Comparative efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer: a systematic review and network meta-analysis.

ABSTRACT:

Background

Although durvalumab or pembrolizumab combined with gemcitabine plus cisplatin (GC) remains the standard first-line therapy, novel targeted agents and immunotherapies integrated with chemotherapy have demonstrated promising efficacy. However, the crosswise comparison between each regimen is rare. Therefore, we comparative the efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer.

Methods

We included 18 randomized controlled trials (RCTs) meeting selection criteria to evaluate first-line targeted/immunotherapy-chemotherapy combinations for advanced BTC. Among them, 15 RCTs were analyzed via Bayesian network meta-analysis (NMA) for the average group, while 6 RCTs were

SUBMITTER: Ma H 

PROVIDER: S-EPMC12798126 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature